Cryptome lures expat home for advisory role
Friday, 14 May, 2004
Melbourne-based proteomics researcher Cryptome Pharmaceuticals has lured Dr Paul Cossum, an Australian who for the last 20 years has worked in American biopharmas, to join the company. As a scientific consultant, Cossum will provide advice on drug development and regulatory affairs.
Both Cossum and recently-appointed Cryptome CEO Dr Jeffrey Travis moved to Australia from positions at early-stage privately-held biopharma NewBiotics Pharmaceuticals in San Diego.
Cossum was executive vice-president of drug development at NewBiotics. He has also worked in pre-clinical development at Arnoex Pharmaceuticals and Isis Pharmaceuticals. He began his career at Genentech, conducting research on recombinant human proteins.
Cryptome's technology uses proteolytic enzymes to break proteins into protein fragments, which are assayed for activity. Its first candidate drug is CR001, is an anti-coagulant compound.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
